Coregulatory Proteins in Nuclear Hormone Receptor Action

Vitamins and Hormones

Volumn 55, Issue C, 1998, Pages 165-218

  Edwards, Dean P ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; CALCIUM BINDING PROTEIN; CALRETICULIN; CHAPERONE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DNA; DNA BINDING PROTEIN; HIGH MOBILITY GROUP PROTEIN; HISTONE ACETYLTRANSFERASE; NUCLEAR PROTEIN; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; RIBONUCLEOPROTEIN; STEROID; STEROID RECEPTOR; STEROID RECEPTOR COACTIVATOR 1; TRANSCRIPTION FACTOR;

DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW; STRUCTURE ACTIVITY RELATION;

ACTIVATING TRANSCRIPTION FACTOR 2; CALCIUM-BINDING PROTEINS; CALRETICULIN; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DNA; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; HIGH MOBILITY GROUP PROTEINS; HISTONE ACETYLTRANSFERASES; HUMANS; MOLECULAR CHAPERONES; NUCLEAR PROTEINS; RECEPTORS, RETINOIC ACID; RECEPTORS, STEROID; RETINOID X RECEPTORS; RIBONUCLEOPROTEINS; STEROIDS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION FACTORS;

EID: 0032617352     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0083-6729(08)60936-X     Document Type: Article

References (226)

1. Ali S., Metzger D., Bornert J.-M., and Chambon P. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J. 12 3 (1993) 1153-1160
2. Allan G.F., Leng X., Tsai S.F., Weigel N.L., Edwards D.P., Tsai M.-J., and O'Malley B.W. Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J. Biol. Chem. 267 (1992) 19513-19520
3. Allan G.F., Lombardi E., Haynes-Johnson D., Palmer S., Kiddow M., Kraft P., Campen C., Rybczynski P., Combs D.W., and Phillips A. Induction of a novel conformation in the progesterone receptor by ZK299 involves a defined region of the carboxyl-terminal tail. Mol. Endocrinol. 10 (1996) 1206-1213
4. Alland L., Muhle R., Hou Jr. H., Potes J., Chin L., Schreiber-Agus N., and DePinho R.A. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature (London 387 (1997) 49-55
5. Almlöf T., Wright A.P.H., and Gustafsson J.-A. Role of acidic and phosphorylated residues in gene activation by the glucocorticoid receptor. J. Biol. Chem. 270 29 (1995) 17535-17540
6. Anzick S.L., Kononen J., Walker R.L., Azorsa D.O., Tanner M.M., Guan X.-Y., Sauter G., Kallioniemi O.-P., Trent J.M., and Meltzer P.S. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277 (1997) 965-968
7. Arnold S.F., Obourn J.D., Jaffe H., and Notides A.C. Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Mol. Endocrinol. 8 (1994) 1208-1214
8. Bagchi M.K., Elliston J.F., Tsai S.Y., Edwards D.P., Tsai M.J., and O'Malley B.W. Steroid hormone-dependent interaction of human progesterone receptor with its target enhancer element. Mol. Endocrinol. 2 (1988) 1221-1229
9. 211 in the chicken progesterone receptor modulates its transcriptional activity. J. Biol. Chem. 271 22 (1996) 12801-12806
10. Bannister A.J., and Kouzarides T. The CBP co-activator is a histone acetyl-transferase. Nature (London 384 (1996) 641-643
11. Bartsch J., Truss M., Bode J., and Beato M. Moderate increase in histone acetylation activates the mouse mammary tumor virus promoter and remodels its nucleosome structure. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 10741-10746
12. Barzel U.S. Estrogen in the prevention and treatment of postmenopausal osteoporosis. Am. J. Med. 85 (1988) 847-850
13. Beato M., and Sanchez-Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocr. Rev. 17 6 (1996) 587-609
14. Beck C.A., Weigel N.L., and Edwards D.P. Effects of hormone and cellular modulators of protein phosphorylation on transcriptional activity, DNA binding, and phosphorylation of human progesterone receptors. Mol. Endocrinol. 6 (1992) 607-620
15. Beck C.A., Zhang Y., Weigel N.L., and Edwards D.P. Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor. J. Biol. Chem. 271 2 (1996) 1209-1217
16. Beebe J.S., Darling D.S., and Chin W.W. 3.5,3'-triiodothyronine receptor auxiliary protein (TRAP) enhances receptor binding by interactions within the thyroid hormone response element. Mol. Endocrinol. 5 (1991) 85-93
17. Beekman J.M., Allan G.F., Tsai S.Y., Tsai M.-J., and O'Malley B.W. Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol. Endocrinol. 7 (1993) 1266-1274
18. Berger S., Pina B., Silverman N., Marcus G.A., Agapite J., Regier J.L., Triezenberg S.J., and Guarente L. Genetic isolation of ADA2: A potential transcriptional adaptor required for function of certain acidic Activation domains. Cell (Cambridge, Mass. 70 (1992) 251-265
19. Berry M., Metzger D., and Chambon P. Role of the two activating domains of the oestrogen receptor in cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamaxifen. EMBO J. 9 (1990) 2811-2818
20. Bhat M.K., Parkison C., McPhie P., Liang C.-M., and Cheng S.-Y. Conformational changes of human β1 thyroid hormone receptor induced by binding of 3,3', 5-triiodo-1-thyronnine. Biochem. Biophys. Res. Commun. 195 1 (1993) 385-392
21. Bhattacharya S., Eckner R., Grossman S., Oldread E., Arany Z., DAndrea A., and Livingston D.M. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-α. Nature (London 383 (1996) 344-347
22. Blanco J.C.G., Wang I.-M., Tsai S.Y., Tsai M.-J., O'Malley B.W., Jurutka P.W., Haussler M.R., and Ozato K. Transcription factor TFIIB and the vitamin D receptor cooperatively activate ligand-dependent transcription. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 1535-1539
23. Bocquel M.T., Kumar V., Stricker D., Chambon P., and Gronemeyer H. The contribution of the N- and C-terminal regions of steroid receptors to activation of transcription is both receptor- and cell-specific. Nucleic Acids Res. 17 (1989) 2581-2595
24. Boonyaratanakornkit V., Melvin V., Prendergast P., Altmann M., Ronfani L., Bianchi M.E., Taraseviciene L., Nordeen S.K., and Allegretto E.A. High mobility group chromatin proteins-1 and -2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells. Mol. Cell. Biol. 18 8 (1998) in press
25. Bourguet W., Ruff M., Chambon P., Gronemeyer H., and Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α. Nature (London 375 (1995) 377-382
26. Brownell J.E., and Allis C.D. Special HATs for special occasions: Linking histone acetylation to chromatin assembly and gene activation. Curr. Opin. Genet. Dev. 6 (1996) 176-184
27. Brownell J.E., Zhou J., Ranalli T., Kobayashi R., Edmondson D.G., Roth S.Y., and Allis C.D. Tetrahymena histone acetyltransferase A: A homolog to yeast Genop linking histone acetylation to gene activation. Cell (Cambridge, Mass. 84 (1996) 843-851
28. Brzozowski A.M., Pike A.C.W., Dauter Z., Hubbard R.E., Bonn T., Engström O., Öhman L., Greene G.L., Gustafsson J.-A., and Cariquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (London 389 (1997) 753-757
29. Burns K., Opas M., and Michalak M. Calreticulin inhibits glucocorticoid-but not cAMP-sensitive expression of tyrosine aminotransferase gene in cultured McA-RH7777 hepatocytes. Mol. Cell. Biochem. 171 1-2 (1997) 37-43
30. Burns L., Duggan B., Atkinson E.A., Famulski K.S., Nemer M., Bleackley R.C., and Michalak M. Modulation of gene expression by calreticulin binding to the glucocorticoid receptor. Nature (London 376 (1994) 476-480
31. Burnside J., Darling D.S., and Chin W.W. A nuclear factor that enhances binding of thyroid hormone receptors to thyroid hormone response elements. J. Biol. Chem. 265 5 (1990) 2500-2504
32. Burris T.P., Nawaz Z., Tsai M.-J., and O'Malley B.W. A nuclear hormone receptor-associated protein that inhibits transactivation by the thyroid hormone and retinoic acid receptors. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 9525-9529
33. Bustin M., and Reeves R. High-mobility-group chromosomal proteins: Architectural components that facilitate chromatin function. Prog. Nucleic Acid Res. Mol. Biol. 54 (1996) 35-93
34. Cavailles V., Dauvois S., Danielian P.S., and Parker M.G. Interaction of proteins with transcriptionally active estrogen receptors. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 10009-10013
35. Cavailles V., Dauvois S., L'Horset F., Lopez G., Hoare S., Kushner P.J., and Parker M.G. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J. 14 15 (1995) 3741-3751
36. Cavanaugh A.H., and Simons Jr. S.S. Glucocorticoid receptor binding to calf thymus DNA. 1. Identification and characterization of a macromolecular factor involved in receptor-steroid complex binding to DNA. J. Biol. Chem. 29 (1990) 989-996
37. Cavanaugh A.H., and Simons Jr. S.S. Factor-assisted DNA binding as a possible general mechanism for steroid receptors. Functional heterogeneity among activated receptor-steroid complexes. J. Steroid Biochem. Mol. Biol. 48 5/6 (1994) 433-446
38. Chakravarti D., LaMorte V.J., Nelson M.C., Nakajima T., Schulman I.G., Juguilon H., Montminy M., and Evans R.M. Role of CBP/p300 in nuclear receptor signalling. Nature (London 383 (1996) 99-103
39. Chen H., Lin R.J., Schiltz R.L., Chakravarti D., Nash A., Nagy L., Privalsky M.L., Nakatani Y., and Evans R.M. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell (Cambridge, Mass. 90 (1997) 569-580
40. Chen J.D., and Evans R.M. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature (London 377 (1995) 454-457
41. Chrivia J.C., Kwok R.P.S., Lamb N., Haiwara M., Montminy M.R., and Goodman R.H. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature (London 365 (1993) 855-859
42. Clemm D.L., Macy B.L., Santiso-Mere D., and McDonnell D.P. Definition of the critical cellular components which distinguish between hormone and anti-hormone activated progesterone receptor. J. Steroid Biochem. Mol. Biol. 53 (1995) 487-495
43. Dahlman-Wright K., and McEwan I.J. Structural studies of mutant glucocorticoid receptor transactivation domains establish a link between transactivation activity in vivo and α-helix-forming potential. in vitro. J. Biol. Chem. 35 (1996) 1323-1327
44. Dahlman-Wright K., Baumann H., McEwan I.J., Almlöf T., Wright A.P.H., Gustafsson J.-A., and Härd T. Structural characterization of a minimal functional transactivation domain from the human glucocorticoid receptor. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 1699-1703
45. Danielian P.S., White R., Lees J.A., and Parker M.G. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptor. EMBO J. 11 (1992) 1025-1033
46. Dedhar S., Rennie P.S., Shago M., Hagesteijn C.-Y.L., Yang H., Filmus J., Hawley R.G., Bruchovsky N., Cheng H., Matusik R.J., and Giguere V. Inhibition of nuclear hormone receptor activity by calreticulin. Nature (London 367 (1994) 480-483
47. Delabre K., Guiochon-Mantel A., and Milgrom E. In vivo evidence against the existence of antiprogestins disrupting receptor binding to DNA. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 4421-4425
48. Desai D., Michalak M., Singh N.K., and Niles R.M. Inhibition of retinoic acid receptor function and retinoic acid-regulated gene expression in mouse melanoma cells by calreticulin. J. Biol. Chem. 271 25 (1996) 15153-15159
49. 4 pathway to inflammation control. Nature (London 384 (1996) 39-43
50. De Vos P., Claessens F., Celis L., Peeters B., Rombauts W., Heyns W., and Verhoeven G. Nuclear extracts enhance the interaction of fusion proteins containing the DNA-binding domain of the androgen and glucocorticoid receptor with androgen and glucocorticoid response elements. J. Steroid Biochem. Mol. Biol. 48 4 (1994) 317-323
51. Ding X.F., Anderson C.M., Ma H., Hong H., Uht R.M., Kushner P.J., and Stallcup M.R. Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): Multiple motifs with different binding specificities. Mol. Endocrinol. 12 2 (1998) 302-313
52. Direnzo J., Soderstrom M., Kurokawa R., Ogliastro M.-H., Ricote M., Ingrey S., Horlein A., Rosenfeld M.G., and Glass C.K. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the itneractions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. Mol. Cell. Biol. 17 4 (1997) 2166-2176
53. Edwards D.P., Kühnel B., Estes P.A., and Nordeen S.K. Human progesterone receptor binding to mouse mammary tumor virus deoxyribonucleic acid: Dependence on hormone and nonreceptor nuclear factor(s). Mol. Endocrinol. 3 (1989) 381-391
54. Eisenmann D.M., Arndt K.M., Ricupero S.L., Rooney J.W., and Winston F. SPT3 interacts with TFIID to allow normal transcription in saccharomyces cerevisiae. Genes Dev. 6 (1992) 1319-1331
55. Enmark E., and Gustafsson J.-A. Orphan nuclear receptors-the first eight years. Mol. Endocrinol. 10 11 (1996) 1293-1307
56. Feavers I.M., Jiricny J., Moncharmont B., Saluz H.P., and Jost J.P. Interaction of two nonhistone proteins with the estradiol response element of the avian vitellogenin gene modulates the binding of estradiol-receptor complex. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 7453-7457
57. Felson D.T., Zhang Y., Hannan M.T., Kiel D.P., Wilson P.W.F., and Anderson J.J. The effect of postmenopausal estrogen therapy on bone density in elderly women. N. Engl. J. Med. 329 (1993) 1141-1146
58. Ferrari S., Harley V.R., Pontiggia A., Goodfellow P.N., Lovell-Badge R., and Bianchi M.E. SRY, like HMG1, recognizes sharp angles in DNA. EMBO J. 11 12 (1992) 4497-4506
59. Forman B.M., Goode E., Chen J., Oro A.E., Bradley D.J., Perlmann T., Noonan D.J., Burka L.T., McMorris T., Lamph W.W., Evans R.M., and Weinberger C. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell (Cambridge, Mass. 81 (1995) 687-693
60. Forman B.M., Ruan B., Chen J., Schroepfer G.J., and Evans R.M. The orphan nuclear receptor LXRα is positively and negatively regulated by distinct products of mevalonate metabolism. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 10588-10593
61. Freedman L.P. Anatomy of the steroid receptor zinc finger region. Endocr. Rev. 13 2 (1992) 129-145
62. Fitsch M., Welch R.D., Murdoch F.E., Anderson I., and Gorski J. DNA allosterically modulates the steroid binding domain of the estrogen receptor. J. Biol. Chem. 267 3 (1992) 1823-1828
63. Gass E.K., Leonhardt S.A., Nordeen S.K., and Edwards D.P. The antagonists RU486 and ZK98299 stimulate progesterone receptor binding to DNA in vitro and in vivo but have distinct effects on receptor conformation. Endocrinology (Baltimore 139 4 (1998) 1905-1919
64. Giese K., Cox J., and Grosschedl R. The HMG domain of lymphoid enhancer factor 1 bends DNA and facilitates assembly of functional nucleoprotein structures. Cell (Cambridge, Mass. 69 (1992) 185-195
65. Gill R.K., Atkins L.M., Hollis B.W., and Bell N.H. Mapping the domains of the interaction of the vitamin D receptor and steroid receptor coactivator-1. Mol. Endocrinol. 12 (1998) 57-65
66. Glass C.K. Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. Endocr. Rev. 15 3 (1994) 391-407
67. Glass C.K., Rose D.W., and Rosenfeld M.G. Nuclear receptor coactivators. Curr. Opin. Cell Biol. 9 (1997) 222-232
68. Goodrich J.A., and Tjian R. TBP-TAF complexes: Selectivity factors for eukaryotic transcription. Curr. Opin. Cell Biol. 6 (1994) 403-409
69. Grosschedi R., Giese K., and Pagel J. HMG domain proteins: Architectural elements in the assembly of nucleoprotein structures. Trends Genet. 10 3 (1994) 94-100
70. Gu W., and Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 c-terminal domain. Cell (Cambridge, Mass. 90 (1997) 595-606
71. Halachmi S., Marden E., Martin G., MacKay H., Abbondanza C., and Brown M. Estrogen receptor-associated proteins: Possible mediators of hormone-induced transcription. Science 264 (1994) 1455-1458
72. Hanstein B., Eckner R., Direnzo J., Halachmi S., Liu H., Searcy B., Kurokawa R., and Brown M. P300 is a component of an estrogen receptor coactivator complex. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 11540-11545
73. Härd T., Kellenbach E., Boelens R., Maler B.A., Dahlman K., Freedman L.P., Carlstedt-Duke J., Yamamoto K.R., Gustafsson J.-A., and Kaptein R. Solution structure of the glucocorticoid receptor DNA-binding domain. Science 249 (1990) 157-169
74. Heery D.M., Kalkhoven E., Hoare S., and Parker M.G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature (London 387 (1997) 733-735
75. Heinzel T., Lavinsky R.M., Mullen T.-M., Söderström M., Laherty C.D., Torchia J., Yang W.-M., Bran G., Ngo S.D., Davie J.R., Seto E., Eisenman R.N., Rose D.W., Glass C.K., and Rosenfeld M.G. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature (London 387 (1997) 43-48
76. Henttu P.M.A., Kalkhoven E., and Parker M.G. AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors. Mol. Cell. Biol. 17 4 (1997) 1832-1839
77. Heyman R.A., Mangelsdorf D.J., Dyck J.A., Stein R.B., Eichele G., Evans R.M., and Thaller C. 9-Cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell (Cambridge, Mass. 68 (1992) 397-406
78. Hong H., Kohli K., Trived A., Johnson D.L., and Stallcup M.R. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 4948-4952
79. Hong H., Kohli K., Garabedian M.J., and Stallcup M.R. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol. Cell. Biol. 17 5 (1997) 2735-2744
80. Hörlein A.J., Näär A.M., Heinzel T., Torchia J., Gloss B., Kurokawa R., Ryan A., Kamel Y., Söderström M., Glass C.K., and Rosenfeld M.G. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature (London 377 (1995) 397-403
81. Horwitz K.B., Jackson T.A., Bain D.L., Richer J.K., Takimoto G.S., and Tung L. Nuclear receptor coactivators and corepressors. Mol. Endocrinol. 10 10 (1996) 1167-1177
82. Hu H.F., Veroni M., DeLuise M., Wakeling A., Sutherland R., Watts C.K., and Zalcberg J.R. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI182, 780. Int. J. Cancer 55 (1993) 873-876
83. Huang Z.J., Edery I., and Rosbash M. PAS is a dimerization domain common to Drosophila period and several transcription factors. Nature (London 364 (1993) 259-262
84. Hughes M.J., Liang H., Jiricny J., and Jost J.-P. Purification and characterization of a protein from HeLa cells that binds with high affinity to the estrogen response element, GGTCAGCGTGACC. J. Biol. Chem. 28 (1989) 9137-9142
85. Huibregtse J.M., Scheffner M., Beaudenon S., and Howley P.M. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 2563-2567
86. Ikonen T., Palvimo J.J., and Jänne O.A. Interaction between the Amino- and Carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J. Biol. Chem. 272 47 (1997) 29821-29828
87. Imhof M.O., and McDonnell D.P. Yeast RSP5 and its human homolog hRPF1 potentiate hormone-dependent activation of transcription by human progesterone and glucocorticoid receptors. Mol. Cell. Biol. 16 (1996) 2594-2605
88. Ing N.H., Beekman J.M., Tsai S.Y., Tsai M.-J., and O'Malley B.W. Members of the steroid hormone receptor superfamily interact with TFIIB (S300-II). J. Biol. Chem. 267 25 (1992) 17617-17623
89. Jackson T.A., Richer J.K., Bain D.L., Takimoto G.S., Tung L., and Horwitz K.B. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol. Endocrinol. 11 (1997) 693-705
90. II30 is present in a district TFIID complex and is required for transcriptional activation by the estrogen receptor. Cell (Cambridge, Mass. 79 (1994) 107-117
91. Janowski B.A., Willy P.J., Devi T.R., Falck J.R., and Mangelsdorf D.J. An oxysterol signalling pathway mediated by the nuclear receptor LXRα. Nature (London 383 (1996) 728-731
92. Jayaraman L., Moorthy N.C., Murthy K.G.K., Manley J.L., Bustin M., and Prives C. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Devel. 12 (1998) 463-472
93. Jenster G., Spencer T.E., Burcin M.M., Tsai S.Y., Tsai M.-J., and O'Malley B.W. Steroid receptor induction of gene transcription: a two-step model. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 7879-7884
94. Jeyakumar M., Tanen M.R., and Bagchi M.K. Analysis of the functional role of steroid receptor coactivator-1 in ligand-induced transactivation by thyroid hormone receptor. Mol. Endocrinol. 11 (1997) 755-767
95. Jordan V.V., Fritz N.F., and Tormey D.C. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration of node-positive patients with breast cancer. Cancer Res. 47 (1987) 624-630
96. Joyeux A., Cavailles V., Balaguer P., and Nicolas J.C. RIP 140 enhances nuclear receptor-dependent transcription in vivo in yeast. Mol. Endocrinol. 11 2 (1997) 193-202
97. Kamei Y., Xu L., Heinzel T., Torchia J., Kurokawa R., Gloss B., Lin S.-C., Heyman R.A., Rose D.W., Glass C.K., and Rosenfeld M.G. A CBP integrator complex mediates transcriptional activation and AP-1 inhibitor by nuclear receptors. Cell (Cambridge, Mass. 85 (1996) 403-414
98. Kedar R.P., Bourne T.H., Powles T.J., Collins W.P., Ashley S.E., Cosgrove D.O., and Campbell S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 343 (1994) 1318-1321
99. Kee B.L., Arias J., and Montminy M.R. Adaptor-mediated recruitment of RNA polymerase II to a signal-dependent activator. J. Biol. Chem. 271 5 (1996) 2373-2375
100. King I.N., de Soyza T., Catanzaro D.F., and Lavin T.N. Thyroid hormone receptor-induced bending of specific DNA sequences is modified by an accessory factor. J. Biol. Chem. 268 (1993) 495-501
101. Klein-Hitpass L., Cato A.C.B., Henderson D., and Ryffel G. Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells. Nucleic Acids Res. 19 (1991) 1227-1234
102. 3 signalling. Nature (London 355 (1992) 446-449
103. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell (Cambridge, Mass. 83 (1995) 813-819
104. Kuil C.W., and Mulder E. Deoxyribonucleic acid-binding ability of androgen receptors in whole cells: Implications for the action of androgens and antiandrogens. Endocrinology (Baltimore 137 (1996) 1870-1877
105. Kuil C.W., Berrevoets C.A., and Mulder E. Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. J. Biol. Chem. 270 46 (1995) 27569-27576
106. Kumar V., and Chambon P. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell (Cambridge, Mass. 55 (1988) 145-156
107. Kupfer S.R., Marschke K.B., Wilson E.M., and French F.S. Receptor accessory factor enhances specific DNA binding of androgen and glucocorticoid receptors. J. Biol. Chem. 268 23 (1993) 17519-17527
108. Kupfer S.R., Wilson E.M., and French F.S. Androgen and glucocorticoid receptors interact with insulin degrading enzyme. J. Biol. Chem. 269 32 (1994) 20622-20628
109. Kwok R.P.S., Lundblad J.R., Chrivia J.C., Richards J.P., Bächinger H.P., Brennan R.G., Roberts S.G.E., Green M.R., and Goodman R.H. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature (London 370 (1994) 223-229
110. Landel C.C., Kushner P.J., and Greene G.L. The interaction of human estrogen receptor with DNA is modulated by receptor-associated proteins. Mol. Endocrinol. 8 (1994) 1407-1419
111. Landsman D., and Bustin M. A signature for the HMG-1 box DNA-binding proteins. BioEssays 15 8 (1993) 539-546
112. Le Douarin B., Zechel C., Garnier J.-M., Lutz Y., Tora L., Pierrat P., Heery D., Gronemeyer H., Chambon P., and Losson R. The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors is fused to B-raf in the oncogenic protein T18. EMBO J. 14 9 (1995) 2020-2033
113. Le Douarin B., Nielsen A.L., Garnier J.-M., Ichinose H., Jeanmougin F., Losson R., and Chambon P. A possible involvement of TIFα and TIF1β in the epigenetic control of transcription by nuclear receptors. EMBO J. 15 23 (1996) 6701-6715
114. Lee J.W., Ryan F., Swaffield J.C., Johnston S.A., and Moore D.D. Interaction of thyroid-hormone receptor with a conserved transcriptional mediator. Nature (London 374 (1995) 91-94
115. Lee J.W., Choi H.-S., Gyuris J., Brent R., and Moore D.D. Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor. Mol. Endocrinol. 9 (1995) 243-254
116. Lee M.S., Kliewer S.A., Provencal J., Wright P.E., and Evans R.M. Structure of the retinoid X receptor α DNA binding domain: A helix required for homodimeric DNA binding. Science 260 (1993) 1117-1120
117. Lees J.A., Fawell S.E., and Parker M.G. Identification of two transactivation domain in the mouse oestrogen receptor. Nucleic Acids Res. 17 (1989) 5477-5487
118. Lefstin J.A., Thomas J.R., and Yamamoto K.R. Influence of a steroid receptor DNA-binding domain on transcriptional regulatory functions. Genes Dev. 8 23 (1994) 2842-2856
119. Leid M. Ligand-induced alternation of the protease sensitivity of retinoid X receptor α. J. Biol. Chem. 269 19 (1994) 14175-14181
120. Leid M., Kastner P., Lyons R., Nakshatri H., Saunders Zacharewski T., Chen J.-Y., Staub A., Garnier J.-M., Mader S., and Chambon P. Purification, cloning and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. Cell (Cambridge, Mass. 68 (1992) 377-395
121. Leidig F., Shepard A.R., Zhang W., Stelter A., Cattini P.A., Baxter J.D., and Eberhardt N.L. Thyroid hormone responsiveness in human growth hormone-related genes. J. Biol. Chem. 267 (1992) 913-921
122. Levin A.A., Sturzenbecker L.J., Kazmer S., Bosakowski T., Huselton C., Allenby G., Speck J., Kratzeisen C.I., Rosenberger M., Lovey A., and Grippo J.G. 9-Cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRα. Nature (London 355 (1992) 359-361
123. L'Horset F., Dauvois S., Heery D.M., Cavailles V., and Parker M.G. RIP-140 interacts with multiple nuclear receptors by means of two distinct sites. Mol. Cell. Biol. 16 11 (1996) 6029-6036
124. Li H., Gomes P.J., and Chen J.D. Receptor-associated coactivator 3, a steroid/nuclear receptor coactivator that is related to steroid receptor coactivator 1 and transcriptional intermediate factor 2. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 8479-8484
125. 3. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 9751-9755
126. Love R.R., Mazess R.B., Barden H.S., Epstein S., Newcomb P.A., Jordan V.C., Carbone P.P., and DeMets D.L. Effects of tamoxifen on bone mineral density in post menopausal women with breast cancer. N. Engl. J. Med. 326 (1992) 852-856
127. Lu X.P., Eberhardt N.L., and Pfahl M. DNA bending by retinoid X receptor-containing retinoid and thyroid hormone receptor complexes. Mol. Cell. Biol. 13 (1993) 6509-6519
128. Luisi B.F., Xu W.X., Otwinowski Z., Freedman L.P., Yamamoto K.R., and Sigler P.B. Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature (London 352 (1991) 497-505
129. Lundblad J.R., Kwok R.P.S., Laurance M.E., Harter M.L., and Goodman R.H. Adenoviral E1A-associated protein p300 as a functional homologue of the transcriptional co-activator CBP. Nature (London 374 (1995) 85-91
130. Mangelsdorf D.J., and Evans R.M. The RXR Heterodimers and Orphan receptors. Cell (Cambridge, Mass. 83 (1995) 841-850
131. Mangelsdorf D.J., Ong E.S., Dyck J.A., and Evans R.M. Nuclear receptor that identifies a novel retinoic acid response pathway. Nature (London 345 (1990) 224-229
132. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schütz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., and Evans R.M. The nuclear receptor superfamily: The second decade. Cell (Cambridge, Mass. 83 (1995) 835-839
133. II28 promotes transcriptional stimulation by activation function 2 of the retinoid X receptors. EMBO J. 15 12 (1996) 3093-3104
134. McDonnell D.P., Clemm D.L., Hermann T., Goldman M.E., and Pike J.W. Analysis of estrogen receptor function in vitro reveals three distinct classes of anti-estrogens. Mol. Endocrinol. 9 (1995) 659-669
135. McInerney E.M., Tsai M.-J., O'Malley B.W., and Katzenellenbogen B.S. Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 10069-10073
136. II135 potentiates transcriptional activation by the AF-2s of the retinoic acid, vitamin D3, and thyroid hormone receptors in mammalian cells. Genes Dev. 11 (1997) 1381-1395
137. Metzger D., Ali S., Bornert J.-M., and Chambon P. Characterization of the amino terminal transcriptional activation function of the human estrogen receptor in animal and yeast cells. J. Biol. Chem. 270 16 (1995) 9535-9542
138. Metzger D., Berry M., Ali S., and Chambon P. Effect of antagonists on DNA binding properties of the human estrogen receptor in vitro and in vivo. Mol. Endocrinol. 9 (1995) 579-591
139. Meyer M.E., Gronemeyer H., Turcotte B., Bocquel M.T., Tasset D., and Chambon P. Steroid hormone receptors compete for factors that mediate their enhancer function. Cell (Cambridge, Mass. 57 (1989) 433-442
140. Meyer M.-E., Pornon A., Ji J., Bocquel M.-T., Chambon P., and Gronemeyer H. Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor. EMBO J. 9 (1990) 3923-3932
141. Michalak M., Burns K., Andrin C., Mesaeli N., Jass G.H., Busaan J.L., and Opas M. Endoplasmic reticulum form of calreticulin modulates glucocorticoid-sensitive gene expression. J. Biol. Chem. 271 46 (1996) 29436-29445
142. ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J. 15 6 (1996) 1292-1300
143. Mukherjee R., and Chambon P. A single-stranded DNA-binding protein promotes the binding of the purified oestrogen receptor to its responsive element. Nucleic Acids Res. 18 19 (1990) 5713-5716
144. Murray M.B., and Towle H.C. Identification of nuclear factors that enhance binding of the thyroid hormone receptor to a thyroid hormone response element. Mol. Endocrinol. 3 9 (1989) 1434-1442
145. Nagpal S., Saunders M., Katner P., Durand B., Nakshatri H., and Chambon P. Promoter context- and response element-dependent specificity of the transcriptional activation and modulating functions of retinoic acid receptors. Cell (Cambridge, Mass. 70 (1992) 1007-1019
146. Nagy L., Kao H.-Y., Chakravarti D., Lin R.J., Hassig C.A., Ayer D.E., Schreiber S.L., and Evans R.M. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell (Cambridge, Mass. 89 (1997) 373-380
147. Nardulli A.M., and Shapiro D.J. Binding of the estrogen receptor DNA-binding domain to the estrogen response element induces DNA bending. Mol. Cell Biol. 12 (1992) 2037-2042
148. Nardulli A.M., Grobner C., and Cotter D. Estrogen receptor induced DNA bending: Orientation or the bend and replacement of an estrogen response element with an intrinsic DNA binding sequence. Mol. Endocrinol. 9 (1995) 1064-1076
149. O'Donnell A.L., and Koenig R.J. Mutational analysis identifies a new functional domain at the thyroid hormone receptor. Mol. Endocrinol. 4 (1990) 715-720
150. Ogryzko V.V., Schiltz R.L., Russanova V., Howard B.H., and Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell (Cambridge, Mass. 87 (1996) 953-995
151. Onate S.A., Estes P.A., Welch W.J., Nordeen S.K., and Edwards D.P. Evidence that heat shock protein-70 associated with progesterone receptors is not involved in receptor-DNA binding. Mol. Endocrinol 5 (1991) 2004
152. Onate S.A., Prendergast P., Wagner J.P., Nissen M., Reeves R., Pettijohn D.E., and Edwards D.P. The DNA-bending protein HMG-1 enhances progesterone receptor binding to its target DNA sequences. Mol. Cell. Biol. 14 5 (1994) 3376-3391
153. Onate S.A., Tsai S.Y., Tsai M.-J., and O'Malley B.W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270 (1995) 1354-1357
154. Onate S.A., Boonyaratanakornkit V., Spencer T.E., Tsai S.Y., Tsai M.-J., Edwards D.P., and O'Malley B.W. The steroid receptor coactivator-one (SRC-1) contains multiple receptor interacting and activation domains that cooperatively enhance the AF-1 and AF-2 domains of steroid receptors. J. Biol. Chem 273 20 (1998) 12101-12108
155. Orti E., Hu L.-M., and Munck A. Kinetics of glucocorticoid receptor phosphorylation in intact cells. J. Biol. Chem. 268 11 (1993) 7779-7784
156. Parker M.G. Structure and function of estrogen receptors. Vitam. Horm. (N.Y. 51 (1995) 267-287
157. Paull T.T., Carey M., and Johnson R.C. Yeast HMG proteins NHP6A/B potentiate promoter-specific transcriptional activation in vivo and assembly of preinitiation complexes. in vitro. Genes Dev. 10 (1996) 2769-2781
158. Pazin M.J., and Kadonaga J.T. What's up and down with histone deacetylation and transcription?. Cell (Cambridge, Mass. 69 (1997) 325-328
159. Pham T.A., Hwung Y.-P., Santiso-Mere D., McDonnell D.P., and O'Malley B.W. Ligand-dependent and -independent function of the transactivation regions of the human estrogen receptor in yeast. Mol. Endocrinol. 6 (1992) 1043-1050
160. Pil P.M., Chow C.S., and Lippard S.J. High-mobility-group 1 protein mediates DNA bending as determined by ring closures. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 9465-9469
161. Pratt W.B., and Toft D.O. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr. Rev. 18 3 (1997) 306-360
162. Prendergast P., Onate S.A., Christensen K., and Edwards D.P. Nuclear accessory factors enhance the binding of progesterone receptor to specific target DNA. J. Steroid Biochem. Mol. Biol. 48 1 (1994) 1-13
163. Prendergast P., Pan Z., and Edwards D.P. Progesterone receptor-induced bending of its target DNA: Distinct effects of the A and B receptor forms. Mol. Endocrinol. 10 (1996) 393-407
164. Rastinejad F., Perlmann T., Evans R.M., and Sigler B.P. Structural determinants of nuclear receptor assembly on DNA direct repeats. Nature (London 375 (1995) 203-211
165. Read C.M., Cary P.D., Crane-Robinson C., Driscoll P.C., and Norman D.G. Solution structure of a DNA-binding domain from HMG1. Nucleic Acids Res. 21 15 (1993) 3427-3436
166. Read C.M., Cary P.D., Crane-Robinson C., Driscoll P.C., Carrillo M.O.M., and Norman D.G. The structure of the HMG box and its interaction with DNA. Nucleic Acids Mol. Biol. 9 (1995) 221-250
167. Reese J.C., and Katzenellenbogen B.S. Differential DNA-binding abilities of estrogen receptor occupied with two classes of antiestrogens: Studies using human estrogen receptor overexpressed in mammalian cell. Nucleic Acids Res. 19 23 (1991) 6595-6602
168. Reese J.C., and Katzenellogen B.S. Examination of the DNA-binding ability of estrogen receptor in whole cells/implications for hormone-independent transactivation and the actions of antiestrogens. Mol. Cell. Biol. 12 (1992) 4531-4538
169. Renaud J.-P., Rochel N., Ruff M., Vivat V., Chambon P., Gronemeyer H., and Moras D. Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature (London 378 (1995) 681-689
170. Rochette-Egly C., Gaub M.-P., Lutz A., Ali S., Scheuer I., and Chambon P. Retinoic acid receptor-β: Immunodetection and phosphorylation on tyrosine residues. Mol. Endocrinol. 66 12 (1992) 2197-2209
171. Roderick H.L., Campbell A.K., and Llewellyn D.H. Nuclear localization of calreticulin in vivo is enhanced by its interaction with glucocorticoid receptors. FEBS Lett. 405 2 (1997) 181-185
172. 3 receptor to its response elements. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 256-260
173. Rubin D.M., Coux O., Wefes I., Hengartner C., Young R.A., Goldberg A.L., and Finley D. Identification of the ga14 suppressor Sug1 as a subunit of the yeast 26S proteasome. Nature (London 379 (1996) 655-657
174. Santen R.J. Editorial: Long term tamoxifen therapy: Can an antagonist become an agonist?. J. Clin. Endocrinol. Metab. 81 (1996) 2027-2029
175. Schwabe J.W.R., Neuhaus D., and Rhodes D. Solution structure of the DNA-binding domain of the oestrogen receptor. Nature (London 348 (1990) 458-461
176. Schwabe J.W.R., Chapman L., Finch J.T., and Rhodes D. The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: How receptors discriminate between their response elements. Cell (Cambridge, Mass. 75 (1993) 567-578
177. II110 subunit of the TFIID complex. J. Biol. Chem. 270 36 (1995) 21331-21338
178. Shago M., Flock G., Hagesteijn C.-Y.L., Woodside M., Grinstein S., Giguere V., and Dedhar S. Modulation of the retinoic acid and retinoid X receptor signaling pathways in P19 embryonal carcinoma cella by calreticulin. Exp. Cell Res. 230 (1997) 50-60
179. Shykind B.M., Kim J., and Sharp P.A. Activation of the TFIID-TFIIA complex with HMG-2. Genes Dev. 9 (1995) 1354-1365
180. Simons Jr. S.S. Structure and function of the steroid and nuclear receptor ligand-binding domain. In: Freedman L.P. (Ed). In "The Molecular Biology of Steroid and Nuclear Hormone Receptors" (1998), Birkhaeuser, Boston 35-104
181. Smith C.L., Onate S.A., Tsai M.-J., and O'Malley B.W. CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 8884-8888
182. Smith C.L., Nawaz Z., and O'Malley B.W. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol. 11 (1997) 657-666
183. Sone T., Ozono K., and Pike J.W. A 55-kilodalton accessory factor facilitates vitamin D receptor DNA binding. Mol. Endocrinol. 5 (1991) 1578-1586
184. Spencer T.E., Jenster G., Burcin M.M., Allis C.D., Zhou J., Mizzen C.A., McKenna N.J., Onate S.A., Tsai S.Y., Tsal M.-J., and O'Malley B.W. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature (London 389 (1997) 194-197
185. Srinivasan G., Patel N., and Thompson E. Heat shock protein is tightly associated with the recombinant human glucocorticoid receptor: Glucocorticoid response element complex. Mol. Endocrinol. 8 (1994) 189-196
186. Arnaud R.St., Prud'Homme J., Leung-Hagesteijn C., and Dedhar S. Constitutive expression of calreticulin in osteoblasts inhibits mineralization. J. Cell Biol. 131 5 (1995) 1351-1359
187. Takeshita A., Yen P.M., Misiti S., Cardona G.R., Liu Y., and Chin W.W. Molecular cloning properties of a full-length putative thyroid hormone receptor coactivator. Endocrinology (Baltimore 137 8 (1996) 3594-3597
188. Takimoto G.S., Tasset D.M., Eppert C., and Horwitz K.B. Hormone-induced progesterone receptor phosphorylation consists of sequential DNA-independent and DNA-dependent stages: Analysis with zinc-finger mutants and the progesterone antagonist ZK98299. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 3050-3054
189. Takimoto G.S., Hovland A.R., Tasset D.M., Melville M.Y., Tung L., and Horwitz K.B. Role of phosphorylation on DNA binding and transcriptional functions of human progesterone receptors. J. Biol. Chem. 271 23 (1996) 13308-13316
190. Tasset D., Tora L., Fromental C., Scheer E., and Chambon P. Distinct classes of transcriptional activating domains function by different mechanisms. Cell (Cambridge, Mass. 62 (1990) 1177-1187
191. Tora L., White J., Brou C., Tasset D., Webster N., Scheer E., and Chambon P. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell (Cambridge, Mass. 59 (1989) 477-487
192. Torchia J., Rose D.W., Inostroza J., Kamei Y., Westin S., Glass C.K., and Rosenfeld M.G. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature (London 387 (1997) 677-683
193. Tremethick D.J., and Molloy P.L. Effects of high mobility group proteins 1 and 2 on initiation and elongation of specific transcription by RNA polymerase II. in vitro. Nucleic Acids Res. 16 (1988) 11107-11123
194. Truss M., and Beato M. Steroid hormone receptors: Interaction with deoxyribonucleic acid and transcription factors. Endocrin Rev. 14 4 (1993) 459-479
195. Tsai M.-J., and O'Malley B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63 (1994) 451-486
196. Tymoczko J.L., Ahern S., Unger A.L., Colby J.L., and Ede G. Identification of a protein from rat liver cytosol that enhances activation of the glucocorticoid receptor. Biochem. J. 256 (1988) 47-52
197. Tzukerman M.T., Esty A., Santiso-Mere D., Danielian P., Parker M.G., Stein R.B., Pike J.W., and McDonnell D.P. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrinol. 8 (1994) 21-30
198. Vegeto E., Allan G.F., Schrader W.T., Tsai M.-J., McDonnell D.P., and O'Malley B.W. The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell (Cambridge, Mass. 69 (1992) 703-713
199. II30 affect estrogen receptor-mediated transcriptional activation. Mol. Endocrinol. 11 (1997) 1009-1019
200. Voegel J.J., Heine M.J.S., Zechel C., Chambon P., and Gronemeyer H. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 15 14 (1996) 3667-3675
201. Wagner B.L., Pollio G., Leonhardt S., Wani M.C., Lee D.Y.-W., Imhof M.O., Edwards D.P., Cook C.E., and McDonnell D.P. 16α-substituted analogs of the antiprogestin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 8739-8744
202. Wagner B.L., Norris J.D., Knotts T.A., Weigel N.L., and McDonnell D.P. The nuclear corepressors NcoR and SMART are key regulators of both ligand and 8-bromo-cAMP dependent transcriptional activity of the human progesterone receptor. Mol. Cell. Biol. 18 3 (1998) 1369-1378
203. Wagner R.L., Apriletti J.W., McGrath M.E., West B.L., Baxter J.D., and Fletterick R.J. A structural role for hormone in the thyroid hormone receptor. Nature (London 378 (1995) 690-697
204. Walfish P.G., Yoganathan T., Yang Y.-F., Hong H., Butt T.R., and Stallcup M.R. Yeast hormone response element assays detect and characterize GRIP1 coactivator-dependent activation of transcription by thyroid and retinoid nuclear receptors. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 3697-3702
205. Webster J.C., Jewell C.M., Bodwell J.E., Munck A., Sar M., and Cidlowski J.A. Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein. J. Biol. Chem. 272 14 (1997) 9287-9293
206. Weigel N.L. Steroid hormone receptors and their regulation by phosphorylation. Biochem. J. 319 (1996) 657-667
207. Weigel N.L., Beck C.A., Estes P.A., Prendergast P., Altmann M., Christensen K., and Edwards D.P. Ligands induce conformational changes in the carboxyl-terminus of progesterone receptors which are detected by a site-directed antipeptide monoclonal antibody. Mol. Endocrinol. 6 (1992) 1585-1597
208. Weir H.M., Kraulis P.J., Hill C.S., Raine A.R.C., Laue E.D., and Thomas J.O. Structure of the HMG box motif in the B-domain of HMG1. EMBO J. 12 4 (1993) 1311-1319
209. Wheeler D.G., Horsford J., Michalak M., White J.H., and Hendy G.N. Calreticulin inhibits vitamin D3 signal transduction. Nucleic Acids Res. 23 16 (1995) 3268-3274
210. Winrow C.J., Miyata K.S., Marcus S.L., Burns K., Michalak M., Capoine J.P., and Rachubinski R.A. Calreticulin modulates in vitro DNA binding but not the in vivo transcriptional activation by peroxisome proliferator-activated receptor/retinoid X receptor heterodimers. Mol. Cell. Endocrinol. 111 (1995) 175-179
211. Winston F. Analysis of SPT genes: A genetic approach toward analysis of TFIID, histones, and other transcription factors of yeast. In: McKnight S.L., and Yamamoto K.R. (Eds). In "Transcriptional Regulation" (1992), Cold Spring Harbor Lab. Press, Cold Spring Harbor, NY 1271-1293
212. Wolffe A.P. Architectural transcription factors. Science 264 (1994) 1100-1101
213. Wolffe A.P., and Pruss D. Targeting chromatin disruption: Transcription regulators that acetylate histones. Cell (Cambridge, Mass. 84 (1996) 817-919
214. Wurtz J.-M., Bourguet W., Renaud J.-P., Vivat V., Chambon P., Moras D., and Gronemeyer H. A canonical structure for the ligand-binding domain of nuclear receptors. Nat. Struct. Biol. 3 1 (1996) 87-94
215. Yang J., and DeFranco D.B. Assessment of glucocorticoid receptor-heat shock protein 90 interactions in vivo during nucleocytoplasmic trafficking. Mol. Endocrinol. 10 (1996) 3-13
216. Yang X.-J., Ogryzko V.V., Nishikawa J.-I., Howard B.H., and Nakatani Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature (London 382 (1996) 319-324
217. Yao T.-P., Segraves W.A., Oro A.E., McKeown M., and Evans R.M. Drosophila ultraspiracle modulates ecdysome receptor function via heterodimer formation. Cell (Cambridge, Mass. 71 (1992) 63-72
218. Yao T.-P., Ku G., Zhou N., Scully R., and Livingston D.M. The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 10626-10631
219. 70, for the androgen receptor in human prostate cells. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 5518-5521
220. Yu K., Bayona W., Kallen C.B., Harding H.P., Ravera C.P., McMahon G., Brown M., and Lazar M.A. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem. 270 41 (1995) 23975-23983
221. Yu V.C., Deisert C., Andersen B., Holloway J.M., Devary O.V., Näär A.M., Kim S.Y., Boutin J.-M., Glass C.K., and Rosenfeld M.G. RXRβ: A coregulator that enhances binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate response elements. Cell (Cambridge, Mass. 67 (1991) 1251-1266
222. Zappavigna V., Falciola L., Citterich M.H., Mavilio F., and Bianchi M.E. HMG1 interacts with HOX proteins and enhances their DNA binding and transcriptional activation. EMBO J. 15 18 (1996) 4981-4991
223. Zhang X.-K., Hoffmann B., Tran P.B.-V., Graupner G., and Pfahl M. Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors. Nature (London 355 (1992) 441-445
224. Zhang Y., Beck C.A., Poletti A., Edwards D.P., and Weigel N.L. Identification of a group of Ser-Pro motif hormone-inducible phosphorylation sites in the human progesterone receptor. Mol. Endocrinol. 9 (1995) 1029-1040
225. Zilliacus J., Wright P.H., Carlstedt-Duke J., and Gustafsson J.-A. Structural determinants of DNA-binding specificity by steroid receptors. Mol. Endocrinol. 9 4 (1995) 389-400
226. Zwilling S., König H., and Wirth T. High mobility group protein 2 functionally interacts with the POU domains of octamer transcription factors. EMBO J. 14 6 (1995) 1198-1208